Role of orexin-A in the ventrolateral preoptic area on components of total energy expenditure
Final Accepted Manuscript
AffiliationUniv Arizona, Dept Nutr Sci
Univ Arizona, Arizona Resp Ctr
MetadataShow full item record
PublisherNATURE PUBLISHING GROUP
CitationCoborn, J. E., DePorter, D. P., Mavanji, V., Sinton, C. M., Kotz, C. M., Billington, C. J., & Teske, J. A. (2017). Role of orexin-A in the ventrolateral preoptic area on components of total energy expenditure. International journal of obesity, 41(8), 1256.
JournalINTERNATIONAL JOURNAL OF OBESITY
Rights© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractIdentifying whether components of total energy expenditure (EE) are affected by orexin receptor (OXR1 and OXR2) stimulation or antagonism with dual orexin receptor antagonists (DORAs) has relevance for obesity treatment. Orexin receptor stimulation reduces weight gain by increasing total EE and EE during spontaneous physical activity (SPA). OBJECTIVE: The purpose of this study was to determine if a DORA (TCS-1102) in the ventrolateral preoptic area (VLPO) reduced orexin-A-induced arousal, SPA, total EE and EE during sleep, rest, wake and SPA and whether the DORA alone reduced total EE and its components. We hypothesized that: (1) a DORA would reduce orexin-A induced increases in arousal, SPA, components of total EE, reductions in sleep and the EE during sleep and (2) the DORA alone would reduce baseline (non-stimulated) SPA and total EE. SUBJECTS/METHODS: Sleep, wakefulness, SPA and EE were determined after microinjection of the DORA (TCS-1102) and orexin-A in the VLPO of male Sprague-Dawley rats with a unilateral cannula targeted towards the VLPO. Individual components of total EE were determined based on time-stamped data. RESULTS: The DORA reduced orexin-A-induced increases in arousal, SPA, total EE and EE during SPA, wake, rest and sleep 1 h post injection (P < 0.05). Orexin-A significantly reduced sleep and significantly increased EE during sleep 1 h post injection (P < 0.05). Furthermore, the DORA alone significantly reduced total EE, EE during sleep (NREM and REM) and resting EE 2 h post injection (P < 0.05). CONCLUSIONS: These data suggest that orexin-A reduces weight gain by stimulating total EE through increases in EE during SPA, rest and sleep. Residual effects of the DORA alone include decreases in total EE and EE during sleep and rest, which may promote weight gain.
Note6 month embargo; published online: 10 April 2017
VersionFinal accepted manuscript
SponsorsUnited States Department of Veterans Affairs Rehabilitation Research and Development Service [F7212W, 5I01RX000441-04]; National Institutes of Health-NIDDK [1R01DK100281-01A1, 5P30DK05045619]; United States Department of Agriculture [ARZT-1360220-H23-150, ARZT-1372540-R23-131]; University of Arizona Department of Nutritional Sciences DeBell Research Enhancement Award; National Needs Fellowship [2014-38420-21799]; University of Arizona College of Agriculture and Life Science Dean's Research Advisory Committee Research Enhancement Award